Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis
Background In the current study, the authors assessed the risks and outcomes of immune checkpoint inhibitor (ICI) rechallenge in patients with resolved grade 3 to 4 ICI hepatitis because current guidelines recommend permanent ICI discontinuation in these patients. Methods The authors performed a ret...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | englanti |
| Julkaistu: |
2020
|
| Linkit: | https://doi.org/10.1002/cncr.33165 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|